Namal Nawana | CEO and President

Jefferies Global Healthcare

Conference

June 1, 2015

New York

© 2015 Alere Inc.

Namal Nawana, CEO and President

Forward-Looking Statements

This presentation contains forward-looking statements within the

meaning of the federal securities laws. This includes all statements

concerning or relating to our ability to improve clinical outcomes,

improve access to care and to reduce healthcare costs. Such forward-

looking statements are estimates reflecting management’s best

judgment based upon current information and involve a number of risks

and uncertainties. Actual results and the timing of certain events could

differ materially from those projected or contemplated by the forward-

looking statements due to numerous factors, including without

limitation, the risks and uncertainties described in our periodic reports

filed with the Securities and Exchange Commission, including our Form

10-K for the year ended December 31, 2014, as well as in our Quarterly

Reports on Form 10-Q. Our Company undertakes no obligation to

update forward-looking statements.

Global Leader in Rapid Diagnostics

#1toxicology testing

and specialty labs2

in

global

$1.4Bin revenue from

outpatient settings

1Bdelivered in 2014

tests

1stCLIA-waived

molecular POC test4

#1of rapid, point

of care tests1

global

provider

#1of POC infectious

disease testing3

global

provider

1 Frost & Sullivan, Global Point-of-Care Testing (POCT) Market, April 2013, p. 71.2 Alere Company Estimates.3 BCC Research, Espicom, Cowen, Calorama, Company Estimates.4 FDA press release, http://www.fda.gov./News-Events/Newsroom/PressAnnouncements/ucm429127.htm.

2014 Revenue Profile

Cardio -metabolic

33%

Toxicology25%

Consumer Other14%

Infectious Disease

28%

BROAD & DIVERSE

CUSTOMER BASE

Markets

North America54%

Europe21%

Asia Pacific13%

Africa, Latin

America12%

GLOBAL

PRESENCE

Geographies

Services20%

Royalties1%

Instruments3%

STRONG RECURRING

REVENUE

Products

Consumables 76%

3

Leading Market Position

OEM & Retail

Reference Lab

Hospitals

Pain mgmt

Government

Workplace

Sexual Health

HAIs

Respiratory

Liver

Tropical disease

HIV

Mail Order Diabetes

Anti Coag Service

Anti Coag Product

Lipids

HbA1c

Blood gas

Cardiac markers

Cardio-

metabolic

Infectious

Disease

Toxicology

Business

4-yr expected

CAGR, %

Market

Market

Position, #

Market Size

$M

280+

250

400

200

220

880

700

100

300

300

1,000

800

1,500

200

250

400

100+

200

350

-3

9

7

8

4

11

4

6

5

3

3

5

13

18

25

14

-7

16

12Emerging

2

1

2

1

1

2

1

1

2

1

2

1

5

6

3

1

1

1

* Company estimates.

*

Rapidly Growing Addressable Markets

2018 Total

Market Opportunity

$17.1B

$6.8B

New Markets

Molecular

Diagnostics

Immunochemistry

Forensics

2018 Existing

Market Growth

$10.3B

Toxicology

Cardio

metabolic

Infectious disease

2013 POC

Addressable Market

$8.4B

Source: Frost and Sullivan, BBC, BCC Research, Espicom, Cowen, Kalorama, Company Estimates

Toxicology

Cardiometabolic

Infectious Disease

Toxicology

Cardiometabolic

Infectious Disease

5

Our Products and Services

Infectious Disease: Global Leader in

Lateral Flow Testing

7

#1Position

>600M

Market leading tests

in HIV, Malaria, Dengue,

Respiratory1

tests sold

in 2014

>190M

malaria

>120

countries

HIV

UAT

Testing

#1

in Flu

tests sold

in 2014

Advocated by

Worldwide

Clinical

Guidelines2

# of countries

that utilize Alere

HIV tests

>50% Market

Share in POL1

1 BCC Research, Espicom, Cowen, Calorama, Company Estimates.2 Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults, Lionel A. Mandell et al; Clinical

Infectious Diseases 2007; 44:S27–72.

Prevention and Diagnosis

Alere HIV Portfolio:

Spanning the Continuum of Care

8

Prevention Monitoring / Management / Care

Staging &

Monitoring

Co-Morbidities

Determine™ HIV 1/2 Ag/Ab

Combo

SD HIV Combo

Alere™ q HIV EID

Alere Pima™ CD4 Analyzer

Alere™ q HIV 1/2 VL

Alere Determine™ TB LAM Ag

Data Point Connectivity

Epocal

Creatinine

Alere™ i:

Disrupting the Market

9

Features Traditional

Lateral FlowLab-based

Molecular Alere i

Molecular Accuracy

Molecular level results allow for improved

sensitivity and specificity

Decentralization

Results at the point of care allow for

feedback and adjustments to care

Rapid Results

Physicians, labs and hospitals desire rapid

tests to improve workflow

Alere™ i Influenza A & B

CLIA Waived

Products:Products:

Cardiometabolic Care Continuum

10

Markets:

Emergency Departments

In-Patient Testing

Products:

Markets:

Office-Based Testing

Pharmacies

Market:

Home Testing

Chronic Chronic at Home

Triage® epoc®

Afinion™ RALS®

LDX® Triage®

INRatio® Afinion™ Nycocard™

Alere™ Home Monitoring

Arriva

Acute

epoc® Blood Analysis System Alere Afinion™ Analyzer Alere™ Home Monitoring

Acute Care Portfolio

11

Alere™ i Alere Triage® System epoc® System 3rd Party POCT

RALS® Data Management System

Leading Solutions. One Partner

Chronic Care Management in Multiple Settings

12

Solutions for:

• Physician practices

• Retail settings

• Home

Early intervention at the point of care,

with ease of use and accessible cost

900+ MinuteClinics® (CVS Health)

have adopted LDX® and Afinion™

systems

Alere Afinion™ AnalyzerAlere Cholestech LDX®

Alere INRatio® 2 NycoCard™

Strategy:Strategies:

Toxicology: Driving Growth

13

Segments:

Employer

Government

Strategies:

Segments:

Pain Lab

Hospital

Segments:

OEM

Reference Lab

Full Solutions

Innovation (Global, Dx Testing)

Stabilize in Pain

Regain Hospital share with new

Triage® Tox product

Launch 8-10 new reagents to

enter untapped markets

Core

Integrated eReader® Triage® Clinical Panel Reagents

Clinical Trade

Comprehensive Toxicology Portfolio

14

Toxicology Products Specialty Lab Services Program Management

25 reagents

32 rapid tests

Small instruments

83 drugs

Urine, saliva, hair

Global Reach

4,000 collection sites

75% ‘e-enabled’

Exclusive e-reader

Integrated

eReader®

Electronic Drug Test

Management

e-Enabled Global Collection NetworkReagents

Rapids

Triage®

Clinical Panel Complex

AnalysisLab

Screening

Mobile Meters

15

Financial Overview

Historical Revenue

$0.00

$500.00

$1,000.00

$1,500.00

$2,000.00

$2,500.00

$3,000.00

$Millions

2010 2011 2012 2013 2014

$1,686.7

$1,946.2

$2,394.4

$2,616.4 $2,588.7

Revenue excludes Alere Health entities sold to Optum in January 2015

2015 Organic Growth

Growth to

accelerate

as year

progresses

Key growth drivers

■ International sales (China, India, Africa,

Latin America)

■ epoc® availability

■ Afinion™

■ Alere™ i (Flu A/B, Strep A)

■ HIV (Determine™ Combo, CD4, Alere™ q)

■ Core Toxicology

■ Toxicology Reagents

Aggressively Paying Down Debt

Q4 2014 Q4 2014

Post Divestitures

Q1 2013

$3.53B$3.35B

$2.77B

18

Note: Figures represent net debt.

Divestiture Initiatives

19(1) EBITDA amounts include equity income earned on 50% interest in SPD and 49% interest in Techlab.

Entity Description

BBI

Wampole/Techlab

SPD

Clinical reagents

Clinical reagents

50% JV with P&G, Women’s Health

Collectively,

businesses

contributed

$184M revenue,

$58.6M EBITDA

in 2014(1)

2015 Revenue and EPS Guidance(As of May 29, 2015)

Revenue

Adjusted

Diluted EPS

$2.5B - $2.6B

$2.40 - $2.50*

* Adjusted diluted EPS excludes restructuring charges, amortization and other items of a similar nature to those excluded in prior

periods. For a summary of adjustments to earnings in 2014, see http://www.alere.com/us/en/about/investor-relations/events.html.

First Quarter 2015 Results

* Please visit http://www.alere.com/ww/en/investor-relations/events.html to view our Q1-15 Press Financials which

contain detailed reconciliations of the non-GAAP financial measures under GAAP.

($ millions, except EPS) GAAP Non-GAAP

Net Revenue $608.2 $608.4

Gross Margin % 48.0 50.7

Total OpEx % 43.5 31.8

R&D % 4.6 4.3

SG&A % 33.1 27.4

Income (Loss) –

Cont. Operations

$(12.9) $45.1

Diluted EPS $(0.15) $0.53

* Please visit: http://www.alere.com/ww/en/investor-relations/events.html to view our Q1-15 Press Financials which contain detailed

reconciliations of the non-GAAP financial measures under GAAP.

Building on Our Momentum

■ Grow at market (>5%)

■ Focus resources on

outpatient

■ Enter MDx

■ International markets

■ Launch new products

■ Double TAM to $17B

by 2018

Growth

■ Rapidly populate existing

platforms

■ Enhance instruments

■ Invest in MDx

■ Quality culture

■ Improve time to market

Innovation

■ OpEx discipline

■ New products drive margin

improvement

■ Global procurement

■ Manufacturing:

- Low cost regions

- Automation/Lean

- Footprint reduction

■ Restructure debt

■ Tax planning

Operating Leverage

© 2015 Alere. All rights reserved. The Alere Logo, Alere, Afinion, Cholestech LDX, Determine, DDS, epoc, eReader, INRatio, Knowing now matters, MeterPro, Pima and Triage are trademarks of

the Alere group of companies.